Arcutis Biotherapeutics Inc. (ARQT)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Arcutis Biotherapeutics, Inc. (ARQT) Q1 2025 Earnings Call Transcript
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Amanda Sheldon - Head of Corporate Communications Frank Watanabe - President and CEO Todd Edwards - CCO Patrick Burnett - Chief Medical Officer Latha Vairavan - CFO Conference Call Participants Vikram Purohit - Morgan Stanley Seamus Fernandez - Guggenheim Securities Uy Ear - Mizuho Tyler Van Buren - TD Cowen Kambiz Yazdi - Jefferies Serge Belanger - Needham Douglas Tsao - H.C. Wainwright Operator Good day and welcome to Arcutis Biotherapeutics' 2025 First Quarter Financial Results Conference Call.
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates
Arcutis Biotherapeutics, Inc. (ARQT) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.32 per share a year ago.
Arcutis Biotherapeutics, Inc. (ARQT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Arcutis Biotherapeutics (ARQT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) have performed compared to their sector so far this year.
Arcutis Opportunity To Capitalize On Leadership, Pipeline, And Commercial Assets
Arcutis Biotherapeutics is rated a buy with a $19 price target, driven by strong Zoryve sales, a solid balance sheet, and strategic CFO transition. CFO David Topper is stepping down, replaced by Latha Vairavan, whose expertise aligns better with Arcutis's current commercial stage and financial goals. Zoryve's performance exceeds expectations, with significant revenue growth and expanded Medicaid coverage, bolstered by a robust sales force.
Arcutis Biotherapeutics (ARQT) Moves 10.8% Higher: Will This Strength Last?
Arcutis Biotherapeutics (ARQT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
How Much Upside is Left in Arcutis Biotherapeutics (ARQT)? Wall Street Analysts Think 25.85%
The consensus price target hints at a 25.9% upside potential for Arcutis Biotherapeutics (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Arcutis Biotherapeutics, Inc. (ARQT) Just Overtook the 50-Day Moving Average
From a technical perspective, Arcutis Biotherapeutics, Inc. (ARQT) is looking like an interesting pick, as it just reached a key level of support. ARQT recently overtook the 50-day moving average, and this suggests a short-term bullish trend.
Wall Street Analysts See a 48.36% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 48.4% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Arcutis: ZORYVE Net Product Revenue Growth Isn't The Only Opportunity On Deck
Data from phase 1b study, using ARQ-255 for the treatment of patients with alopecia areata, expected in the 1st half of 2025. The global alopecia areata market size is expected to be worth $6.92 billion by 2034. Full-year 2024 net product revenue of ZORYVE was $166.5 million, which was a year-over-year growth rate of 471%.
Arcutis Biotherapeutics: Reiterating Strong Buy As Q4 Results Top Expectations
Arcutis Biotherapeutics is a strong buy due to ZORYVE's rapid sales growth and potential for positive earnings within 12 months. ZORYVE, a non-steroidal cream for psoriasis and dermatitis, saw Q4 sales of $69.4M, a 413% YoY increase, beating sales estimates by $10.8M. ZORYVE has maintained quarterly growth of >40% since Q1 2024. Remarkably only one additional quarter of such robust growth will bring sales to a pace needed to achieve profitability.
Arcutis Biotherapeutics, Inc. (ARQT) Q4 2024 Earnings Call Transcript
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Latha Vairavan - Vice President, Finance & Investor Relations Frank Watanabe - President & Chief Executive Officer Todd Edwards - Chief Commercial Officer Patrick Burnett - Chief Medical Officer David Topper - Chief Financial Officer Conference Call Participants Vikram Purohit - Morgan Stanley Tyler Van Buren - TD Cowen Seamus Fernandez - Guggenheim Securities Serge Belanger - Needham & Co. Uy Ear - Mizuho Kambiz Yazdi - Jefferies Douglas Tsao - H.C. Wainwright Operator Good day and welcome to Arcutis Biotherapeutics 2024 Fourth Quarter and Full Year Financial Results Conference Call.
